Pfizer’s COVID-19 pill Paxlovid won another vote of confidence from U.S. health advisers Thursday, clearing the way for its full regulatory approval by the Food and Drug Administration.
emergency use authorization
A panel of outside experts voted 16-1 that Paxlovid remains a safe and effective treatment for high-risk adults with COVID-19 who are more likely to face hospitalization and death due to the virus. The FDA said using Paxlovid in high-risk patients could prevent 1,500 COVID-19 deaths and 13,000 hospitalizations per week.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
FDA panel to meet Thursday to discuss full approval of PaxlovidA Food and Drug Administration committee is set to meet Thursday to decide whether the regulator should grant full approval to Paxlovid, the antiviral pill...
Leer más »
COVID-19 pill Paxlovid moves closer to full FDA approvalU.S. health advisors are backing the continued use of Pfizer’s COVID-19 pill Paxlovid, saying it remains an important option for adults at high risk of severe illness.
Leer más »
COVID-19 pill Paxlovid moves closer to full FDA approvalU.S. health advisersare backing the continued use of Pfizer’s COVID-19 pill Paxlovid, saying it remains an important option for adults at high risk of severe illness.
Leer más »
COVID-19 pill Paxlovid moves closer to full FDA approvalThe medication has been used by millions of Americans since the FDA granted it emergency use authorization in late 2021.
Leer más »
U.S. FDA advisers vote in favor of full approval for Pfizer's COVID pill PaxlovidAdvisers to the U.S. health regulator on Thursday voted in favor of recommending a full approval for Pfizer's COVID-19 pill Paxlovid in adults at high risk of progression to severe disease.
Leer más »
Paxlovid not linked to COVID rebound, FDA saysClinical trial data has concluded that there is no clear association with a COVID-19 rebound.
Leer más »